Cargando…
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
Despite numerous therapeutic advances in the past decade, breast cancer is expected to cause over 42,000 deaths in the United States in 2019. Breast cancer had been considered an immunologically silent tumor; however recent findings suggest that immune cells play important roles in tumor growth even...
Autores principales: | Leal, Ana S., Zydeck, Kayla, Carapellucci, Sarah, Reich, Lyndsey A., Zhang, Di, Moerland, Jessica A., Sporn, Michael B., Liby, Karen T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825145/ https://www.ncbi.nlm.nih.gov/pubmed/31700995 http://dx.doi.org/10.1038/s41523-019-0135-5 |
Ejemplares similares
-
Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008) -
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020) -
The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer
por: Reich, Lyndsey A., et al.
Publicado: (2022) -
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
por: Leal, Ana S., et al.
Publicado: (2021) -
Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray
por: SEO, HYE-SOOK, et al.
Publicado: (2015)